Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7A4QE)

Drug Name

Baxdrostat Drug Info

Synonyms

Baxdrostat; Baxdrostat [INN]; NF3P9Z8J5Y; 1428652-17-8; UNII-NF3P9Z8J5Y; (+)-(R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide; N-((8R)-5,6,7,8-Tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamide; Propanamide, N-((8R)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)-; CIN107; CHEMBL4113975; SCHEMBL14799753; GTPL12362; CIN-107; BDBM233806; GLXC-26998; MS-25786; HY-132809; RO6836191; CS-0204056; US9353081, 3-1; N-[(8R)-4-(1-methyl-2-oxo-3,4-dihydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl]propanamide

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Phase 2	[1]

Cross-matching ID

PubChem CID: 71535962
TTD Drug ID: DM7A4QE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Aldosterone synthase (CYP11B2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MLS-101	DMCP2BJ	Hypertension	BA00-BA04	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aldosterone synthase (CYP11B2)	TT9MNE2	C11B2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405.
2	Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405.
3	ClinicalTrials.gov (NCT05001945) A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Phase 2 Study to Evaluate the Safety, Efficacy, and Tolerability of MLS-101 in Subjects With Uncontrolled Hypertension. U.S.National Institutes of Health.